OrbiMed

Pulnovo Medical, established in 2013 in Wuxi, Anhui, is focused on the development, production, and service provision of innovative medical technologies. The company specializes in creating advanced equipment for treating pulmonary hypertension, particularly through the use of pulse radiofrequency ablation technology. Its core products include pioneering high-frequency ablation equipment and intravascular catheters, which are protected by global invention patents. Pulnovo Medical aims to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure by offering cutting-edge treatment solutions.

Aviceda Therapeutics is a late-stage biotechnology company developing immunomodulators using glycobiology to target innate immune cells and treat chronic inflammation. Its cell-based high-throughput screening platform enables rapid discovery of ligands for various immune cells, with applications in eye diseases, fibrosis, neurology, and oncology.

SiteOne Therapeutics is a San Francisco-based company developing innovative therapeutics and diagnostics for acute and chronic pain. Their lead candidates are selective inhibitors of the Naᵥ1.7 ion channel, aiming to treat pain safely and effectively without relying on NSAIDs or opioids.

Angitia Biopharmaceuticals is a global clinical-stage biotechnology company focused on discovering and developing therapeutics for musculoskeletal diseases, specifically targeting bone, muscle, and joint conditions. Through its research and development activities, it aims to deliver breakthrough therapies that address unmet needs and improve outcomes for patients with severe musculoskeletal disorders.

Kapiva is a producer of ayurvedic nutrition products aimed at enhancing the health and lifestyle of consumers. The company offers a diverse range of over 200 GMP certified products, including ghee, honey, juices, teas, oils, and plant protein powders. Each product is formulated with the right herbs and dosages to address various health concerns effectively. Kapiva emphasizes the use of high-quality herbal extracts, sourced meticulously to ensure optimal results for consumers. The development and testing of these products are conducted by a dedicated team of over 70 doctors and scientists, ensuring their safety and efficacy. Through its commitment to providing natural and authentic nutritional solutions, Kapiva seeks to improve the well-being of its customers and their families.

MBX Biosciences is a biotechnology company focused on developing therapies for endocrine and metabolic disorders, emphasizing rare endocrine diseases with limited treatment options. It pursues discovery, development, and commercialization of first-in-class peptide therapeutics that modulate glandular hormone signaling. MBX has developed a proprietary Precision Endocrine Peptide platform to engineer peptides with extended time-action profiles and consistent drug exposure, aiming to overcome limitations of traditional peptide therapies and improve disease management. Based in Carmel, Indiana, the company advances novel peptide programs through clinical development to address unmet medical needs in endocrine and metabolic disorders.

Founded in 2020 and headquartered in Boston, Massachusetts, Scorpion Therapeutics is a clinical-stage biotechnology company specializing in precision oncology. It develops targeted small-molecule drugs to treat cancer by focusing on three areas: therapies against known oncogenes, agents for currently undruggable targets, and drugs for new targets.

Asceneuron is a biotechnology company dedicated to discovering and developing therapeutics for neurodegenerative disorders with high unmet medical needs. It focuses on orphan tauopathies, Alzheimer's disease, and Parkinson's disease.

Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function. In the three decades since the discovery of the genetic defects that cause cystic fibrosis (CF), researchers have made remarkable advances for patients. Yet the ultimate goal of CF drug development – to fully normalize the function of CFTR, the key protein leading to the pathology of CF – has remained out of reach.

Noctrix Health, Inc. is an early-stage medical device company founded in 2018 and based in Menlo Park, California. The company specializes in developing therapeutic wearable devices aimed at treating chronic neurological and sleep disorders, particularly focusing on conditions such as restless leg syndrome. Noctrix Health's innovative devices leverage neural circuitry to alleviate symptoms, promoting undisturbed sleep and allowing patients to manage their chronic medical conditions more effectively.

ENYO Pharma is a clinical-stage biopharmaceutical company headquartered in Lyon, France, with additional operations in Melbourne, Australia. Founded in 2014, it focuses on discovering and developing antiviral therapies by studying virus-host interactions within the human protein interaction network and leveraging its drug discovery platform to identify intracellular targets and molecules. The company's pipeline includes EYP001, a lead compound that modulates FXR, aiming to reduce the hepatitis B virus cccDNA reservoir and suppress viral transcription, and EYP002 for preclinical development. It also conducts toxicology testing for antiviral candidates against multiple viruses, including influenza, and pursues additional programs aimed at chronic hepatitis B and other infectious diseases. ENYO collaborates with researchers and institutions in Lyon, including Inserm and related biopole ecosystems, to advance its programs through early-stage clinical development and preclinical studies. The company aims to translate virus-host interaction biology into therapeutics for infectious diseases and related liver and metabolic conditions.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

Koya Medical, Inc. is a healthcare company based in Oakland, California, founded in 2018. The company specializes in developing innovative wearable therapeutic devices aimed at treating cancer-related chronic lymphedema and various venous diseases. Koya Medical's technology offers active compression therapy that enhances mobility and personalized care, addressing limitations commonly associated with traditional compression methods. Its sensor-based closed-loop system provides patient-specific patterned compression, enabling healthcare providers to effectively manage conditions like chronic edema and chronic venous insufficiency. Through its breakthrough treatments, Koya Medical seeks to transform the standard of care for individuals affected by these debilitating conditions.

Star Therapeutics aims to develop therapies for numerous rare diseases by identifying those with shared biological pathways. This approach enables the creation of single treatments capable of addressing multiple conditions, thereby expanding pharmaceutical pipelines.

ADARx Pharmaceuticals specializes in the development of RNA editing therapeutics. Founded in 2019, the company focuses on discovering and developing innovative treatments that utilize endogenous enzymes to precisely target and correct single point mutations in mRNA transcripts, restoring the production of functional proteins.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

Acelyrin is a biopharmaceutical company dedicated to advancing treatments for diseases involving excessive immune system activation. It achieves this by discovering, acquiring, and expediting the development and market launch of innovative drug candidates.

Kapiva is a producer of ayurvedic nutrition products aimed at enhancing the health and lifestyle of consumers. The company offers a diverse range of over 200 GMP certified products, including ghee, honey, juices, teas, oils, and plant protein powders. Each product is formulated with the right herbs and dosages to address various health concerns effectively. Kapiva emphasizes the use of high-quality herbal extracts, sourced meticulously to ensure optimal results for consumers. The development and testing of these products are conducted by a dedicated team of over 70 doctors and scientists, ensuring their safety and efficacy. Through its commitment to providing natural and authentic nutritional solutions, Kapiva seeks to improve the well-being of its customers and their families.

MDClone Ltd. is a company that specializes in software development for analyzing medical records. Founded in 2016 and based in Beersheba, Israel, MDClone has created a platform that generates synthetic medical records for fictitious patients, thus mitigating the risk of disclosing actual patient data. This innovative platform, known as ADAMS, provides a self-service analytics environment that facilitates exploration and collaboration across the healthcare ecosystem. By enabling researchers and healthcare organizations to examine disease behaviors, treatment efficacy, and operational efficiencies, MDClone supports the advancement of medical research and improves patient outcomes while ensuring the protection of sensitive medical information. The company serves a diverse clientele that includes major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

Edge Medical Robotics, Inc. is a Shenzhen, China-based company that specializes in the design and development of advanced surgical equipment. Founded on May 4, 2017, the company is dedicated to researching and promoting cutting-edge smart technologies aimed at enhancing surgical safety and treatment efficacy. By focusing on the pursuit of excellence and refinement in its products, Edge Medical Robotics seeks to elevate health standards and improve overall social health outcomes.

Carrot Fertility, Inc. offers comprehensive fertility benefits services for employers, supporting employees throughout their fertility healthcare journey on a global scale. Founded in 2015 and headquartered in San Francisco, California, the company provides a range of services including egg freezing, in vitro fertilization, adoption, donor and gestational carrier services. It also features Carrot Rx, a premium pharmacy experience for fertility medications, and Carrot Pregnancy, which offers virtual access to experts and on-demand doctor-approved content. Additionally, Carrot Card is a flexible debit card that employees can use to pay for fertility care. Carrot Fertility aims to help companies customize their fertility benefits, ensuring that employees receive the necessary financial, medical, and emotional support as they pursue parenthood. The company has expanded its presence with additional offices in major cities including Chicago, New York, Dublin, Geneva, Tokyo, and Seoul.

Insilico is a company specializing in product and material development through innovative methodologies that integrate information technology with materials science. It offers a range of consulting services, including molecular modeling and simulation, regulatory compliance, quality control, and information management for manufacturing and production. By leveraging advanced technology, Insilico aims to deliver efficient and cost-effective solutions for its clients, facilitating streamlined product development processes.

Insilico Medicine, Inc. is a biotechnology company that leverages artificial intelligence (AI) to transform drug discovery, biomarker development, and aging research. Founded in 2014 and based in Baltimore, Maryland, the company has established itself as a pioneer in applying advanced AI techniques, such as generative adversarial networks and reinforcement learning, to create novel molecular structures for various diseases, including cancer and age-related conditions. Insilico Medicine operates an integrated platform that covers all stages of drug discovery, from initial research to clinical trial analysis. Its projects include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, a platform focused on aging predictors. The company also pursues internal drug discovery initiatives targeting diseases like Alzheimer's and Parkinson's, and has partnered with Life Extension to produce nutraceutical products utilizing deep learning and bioinformatics. Additionally, Insilico Medicine provides consumer applications aimed at enhancing health and longevity.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science. The company currently has more than a dozen of independently-developed mRNA drug projects, focusing on the fields of mRNA-based personalized cancer vaccines, mRNA vaccines for infectious disease, protein defects diseases, and genetic diseases, providing cure and solutions for cancer and infectious diseases, better serving patients.

Invivyd is a commercial-stage biopharmaceutical company dedicated to developing and commercializing antibody-based therapies aimed at protecting individuals from serious viral infectious diseases, particularly those with pandemic potential. The company focuses on innovative solutions that surpass the natural limits of immunity, starting with its lead product candidates for SARS-CoV-2. Notable among these candidates are ADG20, designed for the treatment and prevention of COVID-19, and VYD222, a monoclonal antibody optimized for enhanced potency and durability of protection. Invivyd's mission centers on delivering effective, long-lasting therapies to safeguard vulnerable populations from the severe repercussions of ongoing viral threats.

NewMed Medical is a Shanghai-based medical device supplier specializing in interventional artificial heart valve systems. Founded in 2015, the company focuses on researching, developing, manufacturing, and marketing products that include artificial heart valves and transcatheter implantation systems. These products are designed to replace diseased mitral valves, simplifying heart valve replacement surgeries, reducing treatment risks, and enabling faster patient recovery while saving surgery expenses.

Century Therapeutics is a biotechnology company developing allogeneic cell therapies derived from induced pluripotent stem cells to treat cancer and related diseases. Its platform enables engineering of iPSCs into NK and T cells with master cell banks of modified cells that can be expanded and differentiated into standardized, off-the-shelf therapies. The company combines CRISPR-mediated gene editing, proprietary chimeric antigen receptors, Allo-Evasion technology, and manufacturing capabilities to enable scalable production of homogeneous cell products for hematologic and solid tumors. While focused on oncology, its platform also targets autoimmune and inflammatory diseases with the goal of improving cell therapy performance and reducing host immune rejection.

AnchorDx is a biotechnology company specializing in next-generation sequencing techniques, particularly through the use of molecular liquid biopsies. This innovative approach allows for non-invasive access to genetic information, enabling patients to gain insights into their physiological conditions and better prepare for potential health issues. With a core team boasting over 20 years of experience in cancer genomics, genetics, and bioinformatics, AnchorDx aims to lead in precision medicine by developing comprehensive clinical applications and research platforms. The company fosters collaborations with various stakeholders, including hospitals, research institutes, and third-party testing agencies, to create a complete industrial chain that facilitates the transformation of academic research into clinical products. Through its commitment to developing independent intellectual property and competitive clinical testing solutions, AnchorDx provides accurate and comprehensive services to patients, healthcare providers, and medical institutions.

Clover Biopharmaceuticals, established in 2016, is a global, clinical-stage biotech company dedicated to discovering, developing, and commercializing innovative biologics targeting trimerization-dependent pathways in oncology and autoimmune diseases. The company's proprietary Trimer-Tag© technology platform enables the creation of novel biologics. Additionally, Clover employs its in-house cGMP biomanufacturing capabilities for select biosimilars development.

Evox Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, that specializes in developing exosome-based therapeutics for the treatment of severe diseases with limited treatment options. Founded in 2016, the company focuses on harnessing and engineering extracellular vesicles, known as exosomes, to facilitate targeted delivery of nucleic acids and proteins. Evox's innovative platform allows for the modification of exosomes using advanced molecular engineering techniques, enabling effective drug delivery to specific organs, including the brain and central nervous system. By leveraging these natural delivery capabilities, Evox aims to overcome the limitations associated with conventional protein, antibody, and nucleic acid therapies, thereby creating novel therapeutic solutions that could significantly impact human health. The company is supported by a robust intellectual property portfolio and is positioned as a leader in this emerging therapeutic space.

Founded in 2017, Terns Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing molecularly targeted, oral small-molecule drugs for treating cancer and liver diseases. Headquartered in Foster City, California with offices in Shanghai, China, the company focuses on advancing its pipeline of drugs optimized against clinically validated targets.

Immvira, established in Shenzhen, China, in May 2015, is a biotechnology company focused on developing innovative immunotherapy solutions for cancer treatment. Founded by a team of renowned researchers, including Professors from prestigious institutions, Immvira specializes in biopharmaceutical technology centered on oncolytic viruses and vector-based methods. The company’s flagship product is a genetically engineered Oncolytic Herpes Simplex Virus, designed to target metastatic tumors and those that are difficult to reach through traditional injection methods. By leveraging its advanced biotechnology platform, Immvira aims to improve treatment outcomes for cancer patients, providing effective therapeutic options for challenging tumor types.

Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for severe, rare muscle disorders with significant unmet medical need. It employs a holistic drug discovery approach targeting the muscle as an organ, utilizing its proprietary platform to identify precision medicines regulating key proteins in muscle tissue.

Shenzhen Dami He Xiaomi Cultural Broadcast Co., Ltd., known as Dami & Xiaomi, operates an online platform dedicated to supporting children with autism spectrum disorders. Established in 2014 and based in Shenzhen, China, the company offers a range of integrated services including rehabilitation, educational support, parent training, online courses, and science information. Dami & Xiaomi aims to address the needs of children with developmental disorders, focusing on effective strategies to help them manage autism and promote healthy growth. Through its comprehensive platform, it provides essential resources to empower parents and caregivers in their efforts to support their children's development.

Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, specializing in the development of patient-specific immunotherapies designed to combat cancer. Founded in 2016, the company focuses on personalized vaccines and T cell therapies that utilize the body's immune system to target and eliminate cancer cells. Achilles Therapeutics aims to identify and target truncal tumor neoantigens and other markers present on cancer cells, allowing for precise attacks on tumors while sparing healthy tissue. The company is currently conducting clinical trials, including the CHIRON trial for non-small-cell lung cancer and the THETIS trial for recurrent or metastatic melanoma, to evaluate the efficacy and safety of its innovative therapies.

Founded in Hangzhou, China in 2012 by experienced professionals from leading global device makers, Zylox specializes in developing and distributing high-quality interventional and implantable peripheral vascular devices. Its product portfolio includes PTA balloons, drug-coated balloons, SFA stents, and other vascular accessories, aiming to improve patient outcomes worldwide.

Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative cell therapies for cancer treatment. Based in Shanghai, China, Gracell's lead product candidates include GC012F, a dual-targeting autologous CAR-T therapy for multiple myeloma, and GC019F, which targets adult B cell acute lymphoblastic leukemia. Both candidates are currently undergoing Phase I clinical trials. Additionally, the company is advancing GC007F for B cell non-Hodgkin's lymphoma and GC027 for adult T cell acute lymphoblastic leukemia, among others. Gracell also has a range of earlier-stage product candidates addressing various cancer types, such as ovarian cancer and breast cancer. Founded in 2017, the company aims to provide effective cellular therapeutics to improve outcomes for patients with hematological malignancies and solid tumors.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a leading cause of dry eye disease (DED). The company aims to address the root causes of MGD and other ocular surface diseases through a diverse portfolio of compounds and a novel drug delivery platform. By enhancing treatment options in a field where choices are currently limited, Azura seeks to improve the health and well-being of millions affected by these conditions. Headquartered in Tel Aviv-Yafo, Israel, Azura also operates in Australia and the United States, supported by a management team with a strong track record in the development and commercialization of ocular treatments.

Olema Oncology is a preclinical biotechnology company dedicated to developing innovative therapies for the treatment and prevention of estrogen receptor-positive breast cancer. The company specializes in discovering and commercializing targeted treatments specifically designed for women's cancers. By leveraging its extensive understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, Olema aims to create compounds that surpass existing therapies. The company's focus is on transforming the standard of care for both pre- and post-menopausal women with cancer, with an emphasis on developing more effective and convenient treatment options. Olema's pipeline includes drug candidates such as OP-1250 and OP-3136, which have progressed through discovery and preclinical studies.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the development of tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial and is designed as a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast and non-small cell lung cancers. Silverback is also advancing SBT6290, a preclinical candidate targeting Nectin4 in various cancers, and SBT8230, which aims to treat chronic hepatitis B virus infection. The company employs its proprietary ImmunoTAC technology platform to create therapies that can be systemically administered while acting specifically at disease sites, thereby potentially modulating fundamental disease pathways previously considered inaccessible. Founded in 2016, Silverback Therapeutics is committed to innovative approaches in biopharmaceutical development.

Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.

Fore Biotherapeutics is a precision oncology company focused on developing targeted cancer therapies guided by functional genomics. It aims to create a pipeline of treatments for patients with currently unaddressed mutations across established oncology targets.

Kinnate Biopharma Inc. is a biopharmaceutical company dedicated to the discovery and development of small molecule kinase inhibitors aimed at treating genomically defined cancers. Established in 2018 and headquartered in San Diego, California, the company focuses on precision oncology therapeutics, leveraging its expertise in structure-based drug discovery and translational research. Kinnate's lead product candidate, KIN002787, is a rapidly accelerated fibrosarcoma inhibitor currently in preclinical development for lung cancer, melanoma, and other solid tumors. Additionally, the company is advancing other preclinical candidates, including KIN003, which targets cancer-associated alterations in FGFR2 and FGFR3 genes, and a Cyclin-Dependent Kinase 12 inhibitor in the KIN004 program. Kinnate Biopharma is committed to developing targeted therapeutics for underserved patient populations, aiming to expand the reach of precision medicine in cancer treatment.

ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, specializing in the discovery and development of antiviral drugs targeting respiratory syncytial virus (RSV). Founded in 2011, ReViral is focused on creating innovative first-in-class compounds, including a highly potent fusion inhibitor designed specifically for treating severe RSV infections, particularly in vulnerable populations such as neonates. By advancing these novel antiviral treatments, ReViral aims to address significant unmet medical needs and expand the antiviral market, ultimately improving patient outcomes for those affected by RSV.

Prelude Therapeutics is a clinical-stage company developing novel, orally bioavailable small-molecule therapies to target critical pathways in cancer cell growth and resistance. Its pipeline includes four candidates in clinical development targeting MCL1, CDK9, CDK4/6, and SMARCA2/BRM proteins.

MobileODT develops optical diagnostic devices and software for early cancer detection, enabling health care providers to perform visual examinations with portable, internet-connected tools. The Enhanced Visual Assessment system includes the FDA-cleared EVA COLPO portable colposcope and accompanying software to securely store and manage patient data via HIPAA-compliant cloud services such as EVA SANE, and a digital visualization tool for gynecologic exams, EVA WELL. The company also offers a portfolio of aids for screening, including a mobile app for Android that enables remote image capture and patient information tracking, an online portal for collaboration and reporting, and cloud storage solutions for documented patient data. Founded in 2012 and based in Tel Aviv with an additional location in New York, MobileODT aims to extend expert-level diagnostic capabilities to diverse healthcare settings and geographies, including applications in cervical cancer screening and other visual-based diagnostics.

Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases. Established in 2016 with operations in Shanghai, Cambridge, and Rotterdam, the company leverages its proprietary transgenic mouse platforms to generate fully human monoclonal antibodies (H2L2) and heavy chain only antibodies (HCAb), enabling the development of differentiated compounds such as bi-specific and multi-specific antibodies. Harbour BioMed collaborates strategically with various institutions and companies, including The Wistar Institute, WuXi Biologics, and Vir Biotechnology, to advance its pipeline of therapeutics targeting autoimmune diseases, dry eye disease, COVID-19, and other indications.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, dedicated to the discovery, development, and commercialization of innovative treatments for hematological and musculoskeletal disorders with significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is developing KER-047, a small molecule aimed at treating anemia and fibrodysplasia ossificans progressiva, which is currently in Phase 1 clinical trials. Another candidate, KER-012, is being explored for its potential in treating bone loss disorders such as osteoporosis and osteogenesis imperfecta, as well as pulmonary arterial hypertension. Keros Therapeutics emphasizes understanding the role of the Transforming Growth Factor-Beta family of proteins, which are crucial for the regulation of blood cell production and the maintenance of muscle and bone health.

ChemomAb Ltd. is a clinical-stage biotechnology company based in Tel Aviv, Israel, specializing in the development of therapeutic antibodies for autoimmune and inflammatory diseases. The company focuses on addressing fibrosis-related conditions that present significant unmet medical needs. ChemomAb's lead product, CM-101, is a monoclonal antibody designed to inhibit the activity of the soluble protein CCL24, which plays a crucial role in promoting fibrosis and inflammation. CM-101 is currently undergoing clinical development, with a primary emphasis on orphan diseases such as Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc). The company is advancing three Phase 2 clinical trials for CM-101 in various fibrotic indications, with data anticipated to be reported in the near future.

PMV Pharmaceuticals, Inc. is a precision oncology company focused on the discovery and development of small molecule therapies targeting p53 mutations in cancer. Its lead candidate, PC14586, aims to correct and restore the function of the p53 protein, which is critical in regulating cell growth and preventing tumor formation. In addition to PC14586, the company is developing therapies for various p53 hotspot mutations, including the R273H mutation. Founded in 2013 and headquartered in Cranbury, New Jersey, PMV Pharmaceuticals leverages extensive expertise in p53 biology to advance its innovative treatment options for cancer patients.

Arcutis Biotherapeutics is a biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. Its lead product, ZORYVE roflumilast cream, has demonstrated symptomatic improvement in plaque psoriasis patients.

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases affecting the retina and optic nerve. Founded in 2011 and based in Redwood City, California, the company focuses on chronic vision-threatening conditions. Its lead product candidate, GB-102, is an intravitreal injection undergoing clinical trials for wet age-related macular degeneration and diabetic macular edema. Additionally, Graybug is advancing GB-103, a once-a-year formulation aimed at treating diabetic retinopathy, and GB-401, a depot formulation targeting primary open-angle glaucoma. The company utilizes proprietary micro- and nanoparticle controlled release technologies to enhance drug delivery in ocular tissues, thereby improving patient compliance and clinical outcomes. Graybug Vision was previously known as Graybug LLC before its rebranding in 2016.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company focuses on developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By creating enzyme inhibitors designed to disrupt these pathways, Cleave Therapeutics aims to address both oncological and neurodegenerative diseases. Through its innovative approach to drug discovery, the company seeks to provide effective therapeutic solutions that enhance patient outcomes in the fight against cancer.

InventisBio Inc. is a biotechnology company focused on discovering and developing innovative therapeutics for cancer and metabolic diseases. Founded in 2013 and based in Pudong, China, the company has developed a range of small molecule drug candidates targeting lung cancer, breast cancer, and gout. Among its notable products is D-0316, a third-generation EGFR-T790M tyrosine kinase inhibitor. InventisBio is also engaged in creating targeted immuno-oncology therapies that can be used in combination with existing treatments, such as PD-1 antibodies, to address various cancer indications. Co-founded by Dr. Yaolin Wang and a team of scientists with extensive experience in drug discovery at major pharmaceutical companies, InventisBio aims to provide effective therapies for significant health challenges.

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company based in South San Francisco, California, focused on developing a novel class of T cell engagers to harness the body's immune system for treating cancer and other diseases. The company utilizes its proprietary TriTAC (Tri-specific T cell Activating Construct) platform to create engineered proteins that direct T cells to target and kill cells expressing specific antigens. Harpoon's lead product candidate, HPN424, is currently undergoing Phase I clinical trials for metastatic castration-resistant prostate cancer. Additionally, the company is advancing other candidates, including HPN536, which is in Phase I/IIa trials for ovarian cancer and MSLN-expressing tumors, as well as HPN217 for multiple myeloma and HPN328 for small cell lung cancer. Harpoon Therapeutics was founded in 2015 and is committed to addressing unmet medical needs in oncology through innovative therapies.

Galecto is a clinical-stage biotechnology company developing small molecule therapeutics targeting galectin-3 and lysyl oxidase-like 2 for treating severe diseases like fibrosis and cancer. Its lead product candidate, GB0139, is an inhaled inhibitor of galectin-3 for treating severe fibrotic lung diseases such as idiopathic pulmonary fibrosis.

KaNDy Therapeutics is a biopharmaceutical company specializing in the development of non-hormonal treatments for various symptoms associated with menopause, including hot flashes and nighttime awakenings. Founded in 2017 and based in Stevenage, United Kingdom, the company focuses on providing effective therapies for moderate to severe post-menopausal vasomotor symptoms. Its lead product, NT-814, addresses chronic debilitating conditions related to female sex hormones, offering a viable alternative for patients seeking relief without hormonal interventions. As a subsidiary of Bayer Aktiengesellschaft, KaNDy Therapeutics aims to improve the quality of life for women experiencing hormone-related challenges.

Synthorx, Inc. is a biopharmaceutical company specializing in the development of innovative protein therapeutics using advanced synthetic biology techniques. Founded in 2014 and headquartered in La Jolla, California, Synthorx focuses on its proprietary Synthorin programs aimed at treating cancer and autoimmune disorders. Its lead product candidate, THOR-707, is a modified form of recombinant human IL-2, currently being evaluated for various solid tumors both as a standalone treatment and in combination with immune checkpoint inhibitors. The company also develops Synthorins targeting IL-2 for autoimmune conditions, IL-10 for immuno-oncology applications, and IL-15 for regulating immune responses. Synthorx leverages a unique platform that enables the incorporation of synthetic DNA base pairs to enhance the specificity and efficacy of its protein therapeutics, thus offering improved treatment options for patients. Previously known as Alinos, Inc., the company acquired exclusive rights to its synthetic biology technology based on groundbreaking research from The Scripps Research Institute. As of January 2020, Synthorx operates as a subsidiary of Sanofi.

Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of innovative therapies aimed at degrading disease-causing proteins. The company's lead product candidates include ARV-110, a proteolysis targeting chimera (PROTAC) currently in phase I clinical trials for metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. In addition to these, Arvinas is developing various other PROTACs aimed at degrading clinically relevant androgen receptor mutations and treatments for neurodegenerative diseases, including tauopathies. The company has established collaborations with prominent pharmaceutical firms such as Pfizer Inc., Genentech, and Bayer AG, enhancing its research capabilities and reach within the biopharmaceutical landscape. Founded in 2015, Arvinas aims to improve patient outcomes by eliminating harmful proteins from the body through its proprietary technology.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients' lives by developing therapies that overcome resistance in cancer. Its lead product candidate, ORIC-101, targets the glucocorticoid receptor linked to resistance across various solid tumors. ORIC's second product candidate, ORIC-533, inhibits CD73 to address resistance to chemotherapy and immunotherapy. The company is also developing precision medicines targeting other cancer resistance mechanisms.

TytoCare develops handheld devices and software that enable users to perform self-examinations, facilitating remote diagnosis by healthcare professionals. The company's tools allow examination of various body areas and diagnose common conditions. TytoCare offers solutions for consumers (TytoHome), professionals (TytoPro), and remote clinics (TytoClinic). Incorporated in 2011, the company is headquartered in Netanya, Israel with an additional office in New York.

ARMO BioSciences is a biotechnology company based in Redwood City, California, focused on developing immune modulatory biologic therapeutics. The company specializes in immuno-oncology, aiming to activate the immune system of cancer patients to recognize and eradicate tumors. Its pipeline includes several product candidates: AM0010, a long-acting form of interleukin 10 (IL-10) that stimulates the immune system; AM0001, an anti-PD-1 monoclonal antibody; AM0003, an anti-LAG-3 checkpoint inhibitor; AM0015, a form of recombinant human interleukin-15 (IL-15); and AM0012, a form of recombinant human interleukin-12 (IL-12). The company was incorporated in 2010 and formerly known as Targenics.

Zai Lab is a biopharmaceutical company dedicated to discovering and developing transformative medicines for cancer, autoimmune, and infectious diseases. Founded in Shanghai in 2014, the company focuses on bringing innovative therapies to patients worldwide. Zai Lab's pipeline includes proprietary drug candidates such as Niraparib, Optune, Ripretinib, and Margetuximab, among others. The company collaborates with global biopharma leaders to expand its pipeline and foster innovation in China.

Turning Point Therapeutics is a clinical-stage biopharmaceutical company focused on designing and developing novel small molecule targeted oncology therapies. Its pipeline includes repotrectinib, TPX-0046, TPX-0022, and preclinical ALK inhibitor TPX-0131, targeting genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

Founded in 2006, Promentis Pharmaceuticals is a biopharmaceutical company based in Milwaukee, Wisconsin. It develops therapies targeting the central nervous system for treating neuropsychiatric disorders such as impulse control disorders and obsessive-compulsive disorder.

Ornim, Inc. is a biomedical technology company specializing in the development and distribution of non-invasive medical monitoring tools for measuring blood flow and oxygen saturation in patients. Founded in 2004 and based in Santa Clarita, California, with a research and development subsidiary in Israel, Ornim has created innovative products such as the CerOx and c-FLOW monitors. These devices utilize patented UTLight technology, which combines light and ultrasound to deliver real-time, continuous measurements of cerebral blood flow and oxygen saturation. The CerOx monitor is unique in the market for its ability to measure both parameters simultaneously, while the c-FLOW focuses solely on cerebral blood flow. Ornim's solutions are designed to enhance individualized patient care by providing critical insights into blood flow variations, thereby enabling informed clinical interventions. The company holds numerous patents, reflecting its commitment to overcoming the limitations of existing monitoring technologies, and aims to improve treatment outcomes and reduce healthcare costs through its innovative monitoring solutions.

Tricida, Inc. is a late-stage pharmaceutical company based in South San Francisco, California, established in 2013. The company specializes in the development and commercialization of TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis, a common complication of CKD, can accelerate kidney deterioration and is associated with serious health risks, including muscle wasting and loss of bone density. Tricida has successfully completed a Phase 3, double-blind, placebo-controlled trial of TRC101, positioning the company to address a significant unmet medical need in CKD management through the innovative approach of binding and removing acid from the gastrointestinal tract.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for eye diseases using its proprietary Mucus Penetrating Particles (MPP) technology. This technology enhances drug distribution and pharmacokinetics by coating mucosal surfaces with biocompatible, drug-loaded particles, allowing for improved local drug concentrations while minimizing systemic exposure. Kala's lead product candidate, KPI-121 0.25%, has completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS has also completed two Phase III trials for managing inflammation and pain after ocular surgery. The company is advancing KPI-285, a receptor tyrosine kinase inhibitor, in preclinical studies targeting retinal diseases. Established in 2009 and headquartered in Watertown, Massachusetts, Kala Pharmaceuticals continues to explore diverse product opportunities while focusing on internal development and research collaborations to address significant clinical needs.

Acutus Medical designs, manufactures, and markets tools for catheter-based ablation procedures to treat various cardiac arrhythmias worldwide. Its product portfolio includes access sheaths, transseptal crossing tools, diagnostic catheters, ablation catheters, mapping consoles, and supporting software.

ARMO BioSciences is a biotechnology company based in Redwood City, California, focused on developing immune modulatory biologic therapeutics. The company specializes in immuno-oncology, aiming to activate the immune system of cancer patients to recognize and eradicate tumors. Its pipeline includes several product candidates: AM0010, a long-acting form of interleukin 10 (IL-10) that stimulates the immune system; AM0001, an anti-PD-1 monoclonal antibody; AM0003, an anti-LAG-3 checkpoint inhibitor; AM0015, a form of recombinant human interleukin-15 (IL-15); and AM0012, a form of recombinant human interleukin-12 (IL-12). The company was incorporated in 2010 and formerly known as Targenics.

True North Therapeutics is a biotechnology company based in South San Francisco, California, founded in 2013 as a spin-out of iPierian. The company focuses on developing therapies that target the classical pathway of the immune system's complement system to address rare diseases with high unmet clinical needs. Its lead product, TNT009, is a monoclonal antibody designed to selectively inhibit the classical complement pathway, aiming to treat conditions such as cold agglutinin disease, warm autoimmune hemolytic anemia, antibody-mediated rejection, bullous pemphigoid, and other rare diseases in hematologic, kidney transplant, dermatology, and neurological spaces. True North Therapeutics was acquired by Bioverativ Inc.

TigerConnect is a leading provider of secure, real-time communication solutions in healthcare. Its platform facilitates teamwork among doctors, nurses, patients, and care providers through text, video, and voice communication. Trusted by over 4,000 organizations, TigerConnect maintains high uptime and processes millions of messages daily. Headquartered in Santa Monica, California, the company was founded in 2010.

Audentes Therapeutics, a clinical stage biotechnology company based in San Francisco, specializes in developing gene therapy products aimed at treating serious, life-threatening rare diseases resulting from single gene defects. The company is advancing several therapeutic candidates, including AT132 for X-linked myotubular myopathy, AT342 for Crigler-Najjar syndrome, and AT845, which is in preclinical studies for Pompe disease. Additionally, Audentes is developing vectorized antisense treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. It has established collaborative agreements with Genethon and the University of Pennsylvania to further research and commercialization efforts for these therapies. Founded in 2012, Audentes Therapeutics was acquired by Astellas Pharma in January 2020 and operates under the name Astellas Gene Therapies, focusing on gene therapy research, development, and future commercialization.

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes advanced antibody technology and insights from neuroimmunology and human genetics to create innovative treatments. Alector’s pipeline includes several candidates, such as AL001, which is undergoing phase II clinical trials for frontotemporal dementia, and AL101, currently in phase I trials for Alzheimer's and Parkinson's diseases. Additionally, AL002 and AL003 are in phase 1b trials for Alzheimer’s disease. The company is actively engaged in research and development, with a total of ten programs at various stages. Alector has formed a strategic collaboration with Adimab, LLC to enhance its antibody research and development capabilities, aiming to efficiently generate and validate antibody drugs that target key disease-related mechanisms.

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of therapies for cancer treatment. The company's lead candidate, entinostat, is a class I HDAC inhibitor currently in Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, Syndax is advancing SNDX-5613, a selective inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for acute myeloid leukemia with specific mutations. The company also explores entinostat in combination with immunotherapies such as Keytruda and Tecentriq for various cancers, including non-small cell lung cancer and metastatic breast cancer. Furthermore, Syndax is developing axatilimab, a monoclonal antibody targeting the CSF-1 receptor, currently in trials for chronic graft-versus-host disease. The company maintains collaborative relationships with several major pharmaceutical entities and research organizations to enhance its drug development efforts. Founded in 2005, Syndax Pharmaceuticals is committed to advancing innovative treatments for patients with challenging malignancies.

Avitide, Inc. specializes in the discovery, manufacture, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. Founded in 2012 and based in Lebanon, New Hampshire, the company focuses on developing customized affinity purification products that improve the efficiency and effectiveness of bioprocessing. Avitide's technology enhances the purification of therapeutic proteins, including enzymes, antibodies, gene therapies, and vaccines, by employing rapid development of chromatography resins through chemical synthesis. This advanced platform enables clients to accelerate bioprocess development timelines, mitigate program risks, and achieve predictable commercial scalability while lowering manufacturing costs in both batch and continuous operations.

Sikka Software is a pioneering company in the retail healthcare market, offering a cloud-based business intelligence platform that leverages artificial intelligence and predictive analytics. Its award-winning single API platform is designed to support non-physician practices, including dentistry, veterinary care, optometry, chiropractic, orthodontic, and oral surgery. With 35,000 practice installations and connectivity to 96% of the retail healthcare market, Sikka Software enables healthcare providers to optimize their operations through a suite of applications that integrate various practice management and financial systems. The platform hosts 50 applications developed by numerous suppliers, including Fortune 500 companies, alongside four proprietary applications from Sikka. With a vision to create a real-time global platform that connects patients, providers, and suppliers, Sikka addresses a services market exceeding $260 billion annually. The Sikka ONE API was recognized with the Best Health API Award in 2019, highlighting its innovation and impact in the industry.

Otic Pharma is a clinical-stage pharmaceutical company focusing on the development and commercialization of products for disorders of the ear, nose, and throat (ENT). The company has two platform technologies, each of which has the potential to be developed for multiple ENT indications. The company is currently developing a nasally-administered, combination drug product (OP-02) intended to address the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD), a condition that affects more than 700 million people around the world every year. Otitis media is one of the most common disease seen in pediatric practice and the most frequent reason children consume antibiotics or undergo surgery. The company also has a foam-based drug delivery technology platform (OP-01) that can be used to deliver drugs into the ear, nose, and sinus cavities. The company is currently developing OP-01 as an improved treatment option for acute otitis externa (“swimmers ear”). For more information on the company, please visit www.oticpharma.com

Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals to address rare gastrointestinal conditions in infants. Based in Ramat-Gan, Israel, the company has created oral formulations of insulin designed to enhance gut adaptation and rehabilitation in premature infants and children. Its key clinical programs include NTRA-2112, which aims to reduce enteral nutrition intolerance, promote growth velocity and weight gain, and decrease the length of stay in neonatal intensive care units. Another significant product, NTRA-9620, targets short bowel syndrome by improving bowel adaptation post-resection, facilitating enteral nutrition, and minimizing the reliance on parenteral nutrition. Founded in 2003, Nutrinia is committed to improving the health outcomes of vulnerable populations through innovative scientific solutions.

Civitas Therapeutics is a biopharmaceutical company dedicated to the development and commercialization of innovative pulmonary delivery therapies aimed at treating central nervous system and respiratory disorders. Utilizing its proprietary ARCUS technology, Civitas aims to transform the therapeutic landscape for patients across the United States. The company's focus is on creating effective treatments that enhance patient outcomes and address unmet medical needs in these critical areas.

Aerpio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, focused on developing innovative compounds for the treatment of ocular diseases and diabetic complications. The company's lead candidate, razuprotafib, is a small molecule activator of the Tie2 pathway that has completed a Phase IIb clinical trial for diabetic retinopathy. Additionally, Aerpio is advancing ARP-1536, a humanized monoclonal antibody in preclinical development for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, currently undergoing a Phase 1b trial for inflammatory bowel disease. Furthermore, the company is developing a bispecific antibody for the treatment of wet age-related macular degeneration and diabetic macular edema. Aerpio has also partnered with Quantum Leap Healthcare Collaborative to evaluate razuprotafib's potential in treating acute respiratory distress syndrome in COVID-19 patients. Founded in 2011, Aerpio Pharmaceuticals aims for rapid development of its promising therapies.

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, dedicated to developing innovative treatments for central nervous system (CNS) disorders. The company's lead product, ZULRESSO, is an intravenous formulation of brexanolone specifically designed for the treatment of postpartum depression. SAGE Therapeutics is advancing a diverse product pipeline, including SAGE-217, a novel neuroactive steroid in Phase III trials for various depressive disorders and anxiety, and SAGE-324, currently in Phase II trials for essential tremors and other neurological conditions. Additionally, SAGE-718, an oxysterol-based positive allosteric modulator, has completed Phase I trials targeting multiple CNS-related disorders. The company also explores other compounds, such as SAGE-904 and SAGE-689. SAGE Therapeutics has established strategic collaborations with Shionogi & Co., Ltd. and Biogen Inc. for the development and commercialization of its key product candidates, emphasizing its commitment to addressing the challenges of brain health.

Domain Surgical is a medical device company that is creating energy-based surgical products for precise soft tissue cutting and coagulation. It creates energy-based equipment used in specialty surgical procedures. Its patent-pending technology produces surface-only tissue effects with energy that does not pass through the patient designed with the surgical staff in mind, for simple user-interface and training. The company manufactures and markets the FMwand Ferromagnetic Surgical System, a hemostatic dissection device that uses pure thermal energy to cut and coagulate soft tissue, without passing an electrical current through the patient. The FMwand imparts as little as 1/10th the amount of thermal injury compared to traditional electrosurgery devices. The FMwand provides fine dissection with a layer-by-layer precision that is unmatched by existing surgical technology.

Igenica, Inc. is a biotherapeutic company based in Burlingame, California, that specializes in the discovery and development of antibodies and antibody-drug conjugates (ADCs) for cancer treatment. Founded in 2008, the company focuses on creating innovative immunotherapies and functional antibodies targeting tumors. Its product pipeline includes IGN523, a humanized monoclonal antibody for various hematologic and solid tumors; IGN786, an antibody-drug conjugate; and IGN381, an immune checkpoint target that enhances the tumor microenvironment. Igenica operates with a strategic oncology research agreement with MedImmune and is supported by a leadership team experienced in antibody drug discovery and clinical development. As of 2017, Igenica operates as a subsidiary of Pierre Fabre Medicament SA, positioning it to leverage additional resources and expertise in the biotherapeutics field.

Otonomy, Inc. is a biopharmaceutical company based in San Diego, California, specializing in the development and commercialization of therapeutics for ear-related diseases and disorders. The company offers OTIPRIO, a ciprofloxacin otic suspension designed for use during tympanostomy tube placement surgery in pediatric patients. Otonomy is advancing several product candidates, including OTIVIDEX, a sustained-exposure formulation of dexamethasone for treating Ménière’s disease; OTO-313, aimed at treating tinnitus; and OTO-413, which targets cochlear synaptopathy and speech-in-noise hearing difficulties. Additionally, the company is developing OTO-510, an otoprotectant intended to prevent cisplatin-induced hearing loss, and OTO-6XX, which aims to induce hair cell regeneration for severe hearing loss. Otonomy leverages a proprietary formulation platform that allows for sustained drug exposure from a single administration, positioning itself as a leader in localized drug delivery for otic disorders. Founded in 2008, Otonomy focuses its operations primarily in the United States.

Sonendo is a commercial-stage medical technology company that develops dental devices and software to save teeth. It markets the GentleWave System, a root canal therapy platform that cleans and disinfects the microscopic spaces within teeth without removing tooth structure, improving clinical outcomes and practice efficiency. The system includes a console and accessories and integrates with TDO Software, its endodontic practice management software that unifies imaging, practice management, referral reporting, CBCT imaging, and built-in communication with the GentleWave System. Founded in 2006 and based in Laguna Hills, California, Sonendo operates with two business segments: Product, comprising the GentleWave console and instruments, and Software, providing practice management licenses. The company aims to transform dentistry by saving teeth through sound science.

Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, focused on the development and commercialization of innovative medicines for iron deficiency, nephrology, and cardio-renal conditions. Incorporated in 2007, Relypsa specializes in non-absorbed polymeric drugs, aiming to address medical needs in these therapeutic areas. Its flagship product, VELTASSA, is a potassium binder used in the treatment of hyperkalemia, a condition characterized by elevated potassium levels in the blood. The company targets overlooked and undertreated conditions that can be managed through gastrointestinal applications. As of late 2016, Relypsa operates as a subsidiary of Vifor Pharma Ltd.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for progressive non-viral liver diseases. Based in New York, the company’s lead product is Ocaliva, an agonist of the farnesoid X receptor, approved for the treatment of primary biliary cholangitis in adults. Intercept is actively exploring additional indications for Ocaliva, including nonalcoholic steatohepatitis. Furthermore, the company is engaged in the research and development of other drug candidates aimed at addressing chronic liver diseases and metabolic disorders. Intercept has established partnerships for the development and commercialization of its products in specific regions, including agreements with Sumitomo Dainippon Pharma for the Asian markets and Aralez Pharmaceuticals for bezafibrate in the United States. The company employs a multifaceted approach to marketing its products, utilizing an internal commercial organization as well as third-party distributors. Founded in 2002, Intercept Pharmaceuticals continues to advance its mission to address unmet medical needs in liver disease.

Cerapedics, Inc. is an orthobiologics company specializing in the development and commercialization of innovative synthetic small peptide technologies for bone healing. Founded in 2000 and headquartered in Westminster, Colorado, with an additional office in Denver, the company offers products such as i-FACTOR, a peptide-enhanced bone graft designed to stimulate the natural healing process in orthopedic applications, and i-FACTOR+ MATRIX for surgical implantation. Cerapedics focuses on creating biomimetic solutions, specifically its proprietary small peptide molecule (P-15), aimed at improving outcomes in spinal fusion surgery and other orthopedic procedures. The company's technology strives to provide safer and more predictable bone formation compared to traditional bone growth factors.

Sonendo is a commercial-stage medical technology company that develops dental devices and software to save teeth. It markets the GentleWave System, a root canal therapy platform that cleans and disinfects the microscopic spaces within teeth without removing tooth structure, improving clinical outcomes and practice efficiency. The system includes a console and accessories and integrates with TDO Software, its endodontic practice management software that unifies imaging, practice management, referral reporting, CBCT imaging, and built-in communication with the GentleWave System. Founded in 2006 and based in Laguna Hills, California, Sonendo operates with two business segments: Product, comprising the GentleWave console and instruments, and Software, providing practice management licenses. The company aims to transform dentistry by saving teeth through sound science.

Igenica, Inc. is a biotherapeutic company based in Burlingame, California, that specializes in the discovery and development of antibodies and antibody-drug conjugates (ADCs) for cancer treatment. Founded in 2008, the company focuses on creating innovative immunotherapies and functional antibodies targeting tumors. Its product pipeline includes IGN523, a humanized monoclonal antibody for various hematologic and solid tumors; IGN786, an antibody-drug conjugate; and IGN381, an immune checkpoint target that enhances the tumor microenvironment. Igenica operates with a strategic oncology research agreement with MedImmune and is supported by a leadership team experienced in antibody drug discovery and clinical development. As of 2017, Igenica operates as a subsidiary of Pierre Fabre Medicament SA, positioning it to leverage additional resources and expertise in the biotherapeutics field.

Sientra is a medical device company based in Santa Barbara, California, specializing in breast implant treatments for both augmentation and reconstruction. Founded by Hani Zeini, the company develops innovative implantable devices that cater to the needs of plastic surgeons. Sientra's product offerings include silicone gel breast implants, breast tissue expanders, and silicone scar treatment solutions, focusing on providing elegant and intuitive options for cosmetic and reconstructive surgery. The company's commitment to quality and innovation positions it as a significant player in the surgical aesthetics market.

ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

Roka Bioscience specializes in the development of rapid and accurate molecular assays and instrument systems aimed at the food safety industry. The company's latest innovation, the Atlas System, introduces advanced molecular rapid pathogen testing, which enhances laboratory efficiency through automation and user-friendly design. By focusing on innovative testing solutions, Roka Bioscience aims to assist food manufacturers in minimizing risks, safeguarding their brands, and addressing the growing demands for testing in the sector.

Crown Bioscience International is a drug discovery and preclinical research company that provides translational platforms and services to biotech and pharma firms. Its offerings span oncology, cardiovascular, and metabolic disease, including in vivo and in vitro antibodies, bioactive recombinant proteins, recombinant cell lines, tumor cells, immune checkpoint antibodies, and tumor tissue microarrays. The company provides integrated preclinical oncology services and protein science capabilities such as cloning, expression, purification, protein assays, and structural biology to accelerate drug development. It supports evaluation of efficacy, pharmacology, and patient response profiles to improve clinical decision-making and patient stratification. Crown Bioscience collaborates with external centers to license and commercialize genetically engineered models and to deliver organoid-based oncology preclinical development. Founded in 2006 and based in Taipei, Taiwan, Crown Bioscience operates globally through multiple facilities and partnerships to serve biotech and pharmaceutical customers.

Bonovo Orthopedics, Inc. is a provider of orthopedic implants and related products tailored for the Chinese healthcare market. Established in 2005 and headquartered in Scottsdale, Arizona, the company specializes in a wide range of products, including artificial discs, plates, and fixation systems for spinal treatments, as well as hip and knee joint systems and bone void fillers. Bonovo also offers minimally invasive surgical solutions, such as kyphoplasty systems for vertebral fracture management, along with a variety of surgical instruments and devices. With over 15 years of experience in manufacturing and distributing orthopedic products, Bonovo Orthopedics has built strong relationships with leading clinicians and hospitals, positioning itself as a key player in the Chinese orthopedic landscape. The company operates manufacturing facilities in Beijing and Shanghai, further supporting its commitment to providing advanced healthcare solutions.

ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.